Skip to content
Peptidepedia

CJC-1295 Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

Weeks 1–2: Most users report improved sleep quality and more vivid dreams. Some experience mild water retention and increased appetite.

Weeks 2–4: Enhanced recovery from workouts becomes noticeable. Some users report improved skin quality and minor fat loss.

Weeks 4–8: More significant changes in body composition typically emerge, including increased muscle fullness and continued fat reduction. Strength gains may become apparent.

Weeks 8–12: Cumulative effects peak, with users often reporting the most dramatic improvements in lean mass, recovery, and overall body composition. Clinical research supports this timeline, showing IGF-1 levels remained elevated above baseline for up to 28 days with repeated dosing, suggesting cumulative benefits.

Individual responses vary considerably based on age, baseline GH levels, diet, training, and sleep quality.

Frequently Asked Questions

CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 5.8–8.1 days due to its ability to bind to albumin, requiring only once or twice weekly injections. CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes, requiring multiple daily injections but producing a more natural pulsatile GH release pattern.

Most users report improved sleep within 1–2 weeks. Noticeable changes in body composition, recovery, and muscle fullness typically emerge between weeks 4–8, with peak effects occurring around weeks 8–12 of consistent use.

Many users employ CJC-1295 for its potential anti-aging benefits, as elevated GH and IGF-1 levels are associated with improved skin quality, body composition, and recovery. However, long-term safety data for this application is limited.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
  2. Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005.
  3. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
  4. Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009.
  5. Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011.
  6. Aidsmap. Lipodystrophy study halted after patient death. 2006.
  7. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  8. FDA. CJC-1295 - Pharmacy Compounding Advisory Committee Materials. December 2024.
  9. Hone Health. Everything You Need to Know About the FDA Peptide Ban.
  10. Innerbody. CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice.
←Read the full CJC-1295 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”